Artificial intelligence opens up a world of opportunity for us in the digital age (AI). We are constantly reminded of the popularity of AI whether we ask Siri to play a song, gather around a laptop to utilize ChatGPT with friends or spend hours scrolling through Instagram.
The reminder for U of T researchers is provided by potential cancer treatment.
A large biotechnology business called Insilico Medical has teamed up with Alán Aspuru-Acceleration Guzik’s Consortium at the University of Toronto to use AI to improve health care. To hasten the development of research design and development, the Consortium seeks to establish AI labs.
Researchers in this collaboration has developed a viable therapy in less than a month for hepatocellular carcinoma (HCC), a prevalent and aggressive type of liver cancer that claims almost 700,000 lives annually.
The study is the first to utilize AlphaFold, an AI-powered protein structure database, in an end-to-end AI drug development platform called Pharma. AI. It was published in January 2023 in the journal Chemical Science. The platform’s robust biocomputational and generative chemistry engines enable the tool to test countless combinations of possible therapeutics and biochemical pathways.
By locating protein weak spots, these technologies searched for potential HCC therapy targets. One of these weak points was a therapeutic approach that was recently found and focused on the enzymatic enzyme cyclin-dependent kinase 20. (CDK-20).
In the cell cycle, CDKs are essential proteins that help cells develop and divide. These proteins prevent the development of sick or otherwise defective cells as part of their activity, stopping the cell cycle if any defects exist in the new or source cells.
Nevertheless, cellular production still occurs in carcinomas even though the cell is not healthy enough to divide. Tumors develop in this manner.
The cell cycle cannot proceed in the sick cell when CDK enzymes are targeted. To completely stop the growth of malignant cells, this slows it down.
Research to develop a chemical to block the enzymes as part of cancer treatment started after CDK was identified as a critical actor. The resulting medication has so far been tested on living cells and has successfully halted the growth of cancer. Before being put to use, it will still need to undergo clinical studies.
Such a study would have required many years and a great deal of trial and error before the adoption of such technologies. Nevertheless, using AI, was successful in a matter of weeks.
We have daydreamed about the change artificial intelligence (AI) would bring to healthcare: individualized care, more effective solutions, more precise diagnostics, and more. … a……………………………………………………
There are countless options, and this study is just the beginning. A promising cure today might be a treatment tomorrow.
prudent optimism
Yet we must keep in mind the pharmaceutical industry’s two-edged sword as we get closer to promising remedies. Exorbitant prices for life-saving medications and therapies might result from high demand.
It would be ludicrous to assert that the pharmaceutical industry has even started to address these problems. It remains to be seen whether or not these problems can be resolved in the context of AI-driven cancer research. Maybe, therapies will become more readily available to all patients regardless of their socioeconomic level; alternatively, these developing medicines may only benefit those who have the money to pay for them.
